From Yahoo Finance: 2025-05-13 11:11:00

President Trump’s new executive order directs the health department to work with Congress on allowing Medicare to negotiate drug prices, a move long lobbied for by pharmaceutical companies. The order aims to cut healthcare costs and comes amid national security concerns regarding the pharmaceutical industry. Drug makers have sought to delay eligibility for price negotiations for small-molecule drugs by four years, aligning with the 13-year wait for biotech drugs. Medicare’s negotiating powers have been a contentious issue, with drug makers arguing it could stifle innovation. White House officials hint at more savings through negotiation changes compared to the Biden administration’s efforts. Tempus AI, Inc. (TEM) is among the top healthcare stocks to buy now, offering AI-driven healthcare solutions. Analysts are positive about TEM’s strong performance and raised revenue guidance for 2025, highlighting growth in genomics and data businesses. While TEM ranks high for investment potential, other AI stocks may offer higher returns in a shorter time frame.



Read more at Yahoo Finance: Is Tempus AI, Inc. (TEM) the Best Performing Healthcare Stock to Buy Now?